Professor Ian Meredith AM

Professor Ian Meredith

Academic appointment details

  • Professor of Cardiology, Southern Clinical School, Department of Medicine, Monash University
  • Director of MonasHeart, Monash Health
  • Executive Director of Monash Cardiovascular Research Centre


Academic address

Monash Medical Centre
246 Clayton Road, Clayton
Victoria Australia 3168


Academic contact details

Phone:  +61 3 9594 2726
Fax:        +61 3 9594 6939

Summary of qualifications, experience and current interests

Professor Ian Meredith AM BSc(Hons), MBBS(Hons), PhD, FRACP, FACC, FCSANZ, FSCAI

Professor Ian Meredith is the Director of MonashHeart, Monash Health and Professor of Cardiology for Monash University in Melbourne, Australia. He also is Executive Director of the Monash Cardiovascular Research Centre, Monash Health. Following his appointment as director, Professor Meredith had a vision to create a sustainable widely recognised and highly regarded brand, “MonashHeart” comprising of a cohesive team of professionals delivering excellence in patient care. His vision has now come to fruition with MonashHeart, the cross-site cardiology service of Monash Health, with integrated, comprehensive services based at Clayton, Dandenong and Casey. 

Professor Meredith trained in Melbourne and completed his PhD at the Baker Institute. He spent the next three years at the Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, where he trained in interventional cardiology.

Professor Meredith has over 20 years experience as a clinical and interventional cardiologist. He has performed more than 10,000 invasive cardiac and coronary procedures and has been chief investigator or principal investigator for over 30 major international multicentre, randomised trials. His clinical experience includes percutaneous coronary interventions, rotablation, intravascular ultrasound imaging and also structural heart disease which includes PFO and ASD closures and percutaneous aortic valve implantation (TAVI).

Professor Meredith is author or co-author of more than 200 published papers. He is a member of the board of the National Heart Foundation (Vic Division), chair of the 2011 Heart Foundation scientific committee, member of the Cardiac Society of Australia and New Zealand National Board, past chair of the Cardiac Society of Australia and New Zealand (Vic Region), chair of ANZET organizing committee, associate director of Transcatheter Therapeutics (TCT) the world’s largest interventional cardiology meeting and past member of the board of trustees of the International Society of Cardiovascular Angiography and Interventions (SCAI). Professor Meredith also serves on a number of professional and federal government committees and advisory boards, including the Department of Human Services Cardiac Services Review and the Federal Government Department of Health & Aging Cardiac Prostheses Advisory Group.

Professional qualifications

Qualifications - Melbourne University
  • Bachelor of Science B.Sc.(Hons) 1982
  • Bachelor of Medicine, Bachelor of Surgery M.B.B.S. 1982
  • Doctor of Philosophy (Medicine)  Ph.D.  1991
Professional registrations
  • Registered medical practitioner, Australia
Scientific and professional societies
  • Fellow of the Royal Australasian College of Physicians
  • Fellow of the American College of Cardiology
  • Fellow of the Cardiac Society of Australia & New Zealand
  • Fellow of the American Heart Association
  • Fellow of the AHA council on Circulation
  • Fellow of the Society for Cardiovascular Angiography & Interventions
  • Fellow of the Asia Pacific Society of Interventional Cardiology
  • Member of Asia Pacific Society of Cardiology
  • Member of the Association of Monash Medical Graduates
  • Member of the AHA Council on Clinical Cardiology

Current appointments

  • Director of MonashHeart, Monash Health
  • Professor of Cardiology, Southern Clinical School, Department of Medicine, Monash University
  • Executive Director, Monash Cardiovascular Research Centre, MonashHeart, Monash Health
  • Member, Senior Medical Staff, Monash Health,  MonashHeart (Cardiology), Melbourne, Australia
  • Honorary Visiting Physician, The Royal Children’s Hospital, Parkville, Victoria
  • Senior Partner, Melbourne Heartcare, Brighton, Victoria

Awards and honours

  • Hall of Fame, Brighton Grammar School, 2008
  • Finalist – City of Melbourne, Melbourne Awards - Individual Category, Profile, 2007
  • American Federation for Clinical Research - Trainee Investigator Award, 1993
  • NHF Ralph Reader Fellow, 1990
  • Cardiac Society - Bayer Australia ACC Travelling Fellowship, 1989
  • Cardiac Society of Australia and New Zealand, Ralph Reader Prize Young Investigators Award, 1988
  • Robert Power Scholarship in Surgery, Final Year Prize, Alfred Hospital Clinical School, 1982
  • Harriet Power Scholarship in Medicine, Final Year Prize, Alfred Hospital Clinical School, 1982

Committee memberships

  • 2009-present: Chair, Organising Committee 2011 Heart Foundation Scientific Committee
  • 2007-present: Convener, ANZET Australian and New Zealand Endovascular therapies Meeting
  • 2007: Department of Human Services Victoria – Cardiac Services Advisory Committee
  • 2007: Therapeutics Goods Association – Cardiac Expert Working Group
  • 2006: Department of Human Services Victoria – Expert Panel for Safer Systems Saving Lives: Improving Care for Acute Myocardial Infarction toolkit
  • 2005-present: International Committee, Transcatheter Cardiovascular Therapeutics
  • 2005-present: Board Member, National Heart Foundation, Victoria Division
  • 2004-2005: Department of Human Services Victoria - Clinical Advisory Group on Drug-eluting Stents
  • 2004-present: Department of Health & Aging – Cardiac Prostheses and Devices Clinical Advisory Group to the Prostheses and Devices Committee
  • 2000: Department of Health & Aged Care – Professional Services Review
  • 2000: Department of Health & Aging – Medicare Services Advisory Committee -coronary rotablation review committee
  • 1997-2004: Chien Foundation Advisory Board – Singapore
  • 1996-2000: National Heart Foundation, National PTCA Database Committee
  • 1996-present: Asia-Pacific Society of Interventional Cardiology Advisory Board

Research interests

Main research interests include:
  • Interventional cardiology
    • Percutaneous aortic valve implantation technologies and clinical outcomes
    • Novel devices for the treatment of coronary bifurcation lesions
    • New drug-eluting stent designs
    • Drug eluting stents in acute myocardial infarction and complex coronary anatomy
    • Intravascular ultrasound assessment of coronary stent dynamics
    • Antiplatelet and antithrombotic therapies in coronary interventions
    • Percutaneous catheter-based treatment of hypertrophic cardiomyopathy
    • Haemodynamic evaluation of indeterminate and intermediate severity coronary lesions
  • Other clinical research interests
    • Arterial mechanical properties and their influence on coronary blood flow regulation
    • Determinants of metabolic vasodilation in cardiac and skeletal musculature
    • The role of endothelium-derived factors in human coronary vascular control
    • Intravascular ultrasound determined indices of coronary atherosclerotic plaque vulnerability
    • Inflammatory markers in atherosclerosis, role in predicting acute coronary syndromes



Meredith IT. Some Aspects Of The Physiology And Pathophysiology Of Human Cardiac Sympathetic Nerves. Doctor of Philosophy (Medicine), Monash University. 1991

Top 14 peer reviewed articles in scientific journals

1.    Meredith IT, Worthley S, Whitbourn R, Walters D, McClean D, Ormiston J, Horrigan M, Wilkins G, Hendriks R, Matsis P, Muller D, Cutlip DE for the Resolute Investigators. Long-term outcomes with the next-generation Endeavor Resolute Stent System: a report of two year follow-up from the RESOLUTE clinical trial. EuroIntervention 2010;5:692-697

2.    Meredith IT, Omiston J, Whitbourn R, Kay IP, Muller D, Cutlip DE on behalf of the ENDEAVOR I investigators.  Five Year Clinical Follow-Up after Implantation of the Endeavor Zotarolimus-Eluting Stent: ENDEAVOR 1, first-in-human study.  Cathet & Cardiovasc Intervent.  2009;74(7):989-995

3.    Meredith IT, Ormiston J, Whitbourn R, Kay I P, Muller D, Popma JJ, Cutlip DC, Fitzgerald PJ on behalf of the Endeavor I Investigators.  Four-Year Clinical Follow-Up after Implantation of the Endeavor Zotarolimus-Eluting Stent: ENDEAVOR I, the First-in-Human Study.  Am J Cardiol 2007; 100 [Suppl]:56M-61M

4.    Meredith IT, Worthley SG, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P on behalf of the Endeavor Resolute Investigators.  The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Resolute first-in-man trial. EuroInterv 2007;3:50-53

5.    Meredith IT, Ormiston J Whitbourn R, Kay IP, Muller DJ, Bonan R, Popma JJ, Cutlip DE, Fitzgerald PJ, Prpic R, Kuntz RE.  First-in-Human Study of the Endeavor ABT-578-Eluting Phosphorylcholine-Encapsulated Stent System in de novo Native Coronary Artery Lesions: Endeavor I Trial. EuroInterv 2005;2:157-164

6.    Ang P Ch, Harper RW, Farouque HM O, Meredith IT.   Percutaneous Coronary Interventions (PCI) in the Elderly:  A comparison of Procedural and Clinical Outcomes between their Eighth and Ninth Decade.   J Invasive Cardiol 2000; 12(10): 488-494

7.    Skyrme-Jones RAP, Luo M, O’Brien RC, Meredith IT.   Endothelial Vasodilator Function is Related to Low-Density Lipoprotein Particle Size and Low-Density Lipoprotein Vitamin E Content in Type 1 Diabetes.   J Am Coll Cardiol. 2000; 35 (2): 292-9

8.    Duffy SJ, Castle SF, Harper RW, Meredith IT.  Contribution of Vasodilator Prostanoids and Nitric Oxide to Resting Flow, Metabolic Vasodilation and Flow-Mediated Dilation in Human Coronary Circulation.   Circulation. 1999; 100: 1951-1957.

9.    Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA.  Post-Ischemic Vasodilation in the Human Forearm is Dependent on Endothelium-Derived Nitric Oxide.  Am J Physiol 1996;270 (4): 1435-1440.

10.    Meredith IT, Alison J, Zhang F-M. Horowitz JD, Harper RW.  Captopril potentiates the effects of nitroglycerin in the coronary vascular bed.  J Am Coll Cardiol 1993; 22(2):581-587.

11.    Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD.  Cardiac Sympathetic Nervous Activity In Congestive Heart Failure: Evidence For Increased Neuronal Norepinephrine Release and Preserved Neuronal Uptake.  Circulation 1993; 88:136-145.

12.    Meredith IT, Eisenhofer G, Lambert GW, Jennings GL, Thompson J, Esler MD.  Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure.  Hypertension 1992; 19:628-633.

13.    Meredith IT, Esler MD, Jennings GL, Broughton A.  Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias.  New Eng J Med 1991; 325:618-24.

14.    Meredith IT, Friberg P, Jennings GL, Dewar EM, Fazio VA, Lambert GW, Esler MD.  Exercise training lowers resting renal but not cardiac sympathetic activity.  Hypertension 1991; 18:575-582.

Selection of recent invited international and national participation

Japanese Society of Interventional Cardiology & Cardiovascular Intervention & Therapeutics, 25th – 27th June 2009 Sapporo, Japan.  “Zotarolimus-eluting Stent”, “Consider patient and lesion specifics in choice of DES”.

CSANZ 57th Annual Scientific Meeting.  Sydney 13-16th August 2009.  August 14th “Fractional Flow and decisions in the Cath Lab”, “Controversies in Structural Heart Disease: “Best done in the Cath Lab”, DES: Questions that need answering – “Are drug-eluting stents better than bare metal stents”, DES: Questions that need answering – “What do the next generation DES have to offer”?

Great Minds Symposium, Singapore.  August 22nd -23rd 2009.  August 23rd “Transcatheter Aortic Valve Replacement – How to enter this arena”?,   Interventional Cardiology 2020: “Structural Heart Disease”.

Transcatheter Cardiovascular Therapeutics 2009 (TCT ’09), San Francisco. 21st – 25th September 2009. “A Snapshot from the Ongoing Australia-New Zealand Medtronic CoreValve TAVI Registry”,’09), “The Medtronic Y-Stent: Design Specifications and Clinical Trial Results”, “Are the Immediate Results of Alcohol Septal Ablation Sustained? Ten-Year Results”, “Hot Topics I: Fully Bioabsorbable Stents.”, “The Asia Pacific Region has Become a Global Center for First-In-Man Studies and New Device Development”, “Fully Bioabsorbable Devices: Potential for Improved Durability of Results”, “Late Breaking Clinical Trials I, Roundtable Discussion.”, “Will New Technology Impact DES Clinical Safety Outcomes?”, “Second Battle: In Whom Should Aspiration Thrombectomy be Used During Primary PCI? “ Third Battle: Should All Patients Undergoing Primary PCI Receive Bivalirudin? What About GPIIB/IIIa Inhibitors?”, “Final Battle: Approach to the Patient With STEMI Presenting at a non PCI Facility”.

Australian College for Emergency Medicine 26th Annual Scientific Meeting, Melbourne. November 15th – 19th 2009. November 16th “Non invasive CT coronary angiography: a new paradigm in acute coronary artery (heart) disease management”, for Sanofi-Aventis, “StEMI and the ED – a Paradigm Shift”.

International Technology Exchange Meeting, Sydney. November 18th – 21st 2009. November 19th with Zidar J, “Interventional Cardiology: Current Perspectives”,with Zidar J, “How to treat Multi-Vessel Disease”, with Gershlick A, “How to treat Thrombus Bearing Lesions”, with Gershlick A, “How to Treat Coronary Artery Disease in the Diabetic Patient”, November 21st with Kandzari D, “How to treat Aortic Valve Stenosis”.

Complex Cardiovascular Therapeutics 2010. Kobe, Japan January 27th-31st.  “New Frontier: Fully Bioabsorable Stent Technology”,  “Future DES Technology”, “Fully Bioabsorbable Devices: Improved Durability of Results”.

Australian Synchrotron: Clinical Applications of Radiation Workshop.February 20th Melbourne.  “Identifying the characteristics of vulnerable atherosclerotic plaques”

ACC/i2Summit 2010.  Atlanta, GA USA.  13th – 18th March 2010.  “Optimising PCI Outcomes: Complex PCI with Second Generation Stent”,  “Immediate future - Resolute update and what to expect from R-AC”, “Overview of BVS Technology”, “DES: Assessing the Growing Body of Evidence- "Bioasbsorbable Stents: Does the Data show promise in CAD"?

China Interventional Therapeutics 2010.  31st March – 4th April 2010.  Beijing, China. "Element Clinical Programs: PERSEUS Late Breaking News and PLATINUM Study Design”,  "Are Dedicated Stents necessary for most "True" Bifurcation Lesions in the Future?", “Fully Bioabsorbable Stent: Revolutionary Prospect, is it a Paramount Innovation in Cardiology”.

TCT- AP Summitmd meeting.  28th -30th April 2010.  Seoul, Korea. "Relevant clinical designs: balancing regulatory & medical evidence needs.”, “The Role of the Interventional Cardiologist- What does the future hold? "Unique Intervention Challenges in AP",  “PtCr ELEMENT Clinical Programs: PERSEUS & PLATINUM Clinical Data.”

Australia & New Zealand Optical Coherence Workshop. (ANZOCT).  7th May 2010. Melbourne.“Emerging Technologies in DES”.

EuroPCR 2010. Paris 24-28th May 2010.  “How should I treat multivessel complex disease in Asia?”,  “How should I treat a patient presenting to the cath lab in 2010 with a STEMI, directly or after thrombolysis?”, Designing the future percutaneous coronary intervention: the ELEMENT stent technology and beyond: “Lessons from recent trials.”

XXXII Brazilian Congress of Interventional Cardiology.   21st – 24th July 2010.  Belo Horzonte, Brazil. OPTIMIZE Meeting: “Long-term Follow up of the Endeavour Stent: Safety comes first.”, “Bioresorbable vascular scaffolds: remote and uncertain reality”, “Are there differences in safety and efficacy among DES for the treatment of diabetics.”

The 4th Annual Australia and New Zealand Endovascular Therapies Meeting 2010 (ANZET’10). 4-5 August 2010. Adelaide, Australia. “The new stent platform from alloy to the design and the implications it has in clinical practice including the clinical program of the Promus™ Element™ and Taxus™ Element™ stent series”.

The 58th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ2010). 5th to 8th August 2010. Adelaide, Australia. “Interventional Research: The Australian and New Zealand Experience”. 

Higher degree by research supervision

  • 2011-present: Dr Arthur Nasis (PhD Scholar): Use of novel imaging techniques for the diagnosis of coronary artery disease and myocardial ischaemia: implications for the assessment of patients with chest pain

  • 2009-present: Dr Adam Hutchison (PhD Scholar): Approaches to optimising outcomes in ST-elevation and non-ST elevation myocardial infarction

  • 2002-2005: Dr Michael Leung (NH & MRC postgraduate PhD Scholar): Insights into the human coronary microvasculature – The influence of aortic mechanical properties and coronary artery disease

  • 2001-2003: Dr Sarah Hope (Monash University International and Faculty postgraduate research scholarship from Monash University and a Cardiovascular Research Centre  PhD scholarship from Monash Medical Centre PhD Scholar): Arterial pressure waves: waveform characteristics, their associations and factors influencing their propagation

  • 2000-2001: Dr Stephen Worthley (Monash University post doctoral PhD Scholar): Characterisation of atherosclerotic plaque composition in the carotid artery with high resolution magnetic resonance imaging: Case control study of patients with carotid disease and acute cerebral events

  • 1997-2000: Dr Sue Wigg (NH & MRC Postgraduate PhD Scholar): The role of advanced glycation in the vascular dysfunction of diabetes

  • 1999- 2002: Dr Omar Farouque (NH & MRC Postgraduate PhD Scholar):  The role of ATP- sensitive potassium channels in metabolic vasodilation within the human forearm and coronary circulations

  • 1996-2000: Dr Andrew Skyrme-Jones (Diabetes Australia Postgraduate PhD Scholar): Aspects of vascular regulation and endothelial function in type 1 diabetes mellitus

  • 1995-1998: Dr Stephen Duffy (NH&MRC Postgraduate PhD Scholar): Aspects of local vascular regulation of skeletal muscle and myocardial blood flow

  • 1995-1998: Dr Gishel New (Monash University PhD Scholar): The effects of estrogen on vascular function and lipoproteins in biological males